Advanced search
Publication Cover
Acta Orthopaedica Volume 85, 2014 - Issue 3
Journal homepage
1,720
Views
55
CrossRef citations to date
0
Altmetric
Hip and femur

Histology of 8 atypical femoral fractures

Remodeling but no healing

Jörg SchilcherOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Science, Linköping UniversityCorrespondence[email protected]
,
Olof SandbergOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Science, Linköping University
,
Hanna IsakssonDivision of Solid Mechanics and Department of Orthopedics, Lund University, Sweden.
&
Per AspenbergOrthopedics Section, Department of Clinical and Experimental Medicine, Faculty of Health Science, Linköping University
Pages 280-286 | Received 04 Aug 2013, Accepted 20 Feb 2014, Published online: 30 Apr 2014

  • Aspenberg P, Schilcher J, Fahlgren A. Histology of an undisplaced femoral fatigue fracture in association with bisphosphonate treatment. Acta Orthop 2010; 81 (4): 460–2.
  • Bauer DC. Atypical femoral fracture risk in patients treated with bisphosphonates. Arch Intern Med 2012; 172 (12): 936–7.
  • Boskey AL, Spevak L, Weinstein RS. Spectroscopic markers of bone quality in alendronate-treated postmenopausal women. Osteoporos Int 2008; 20 (5): 793–800.
  • Burr DB. Targeted and nontargeted remodeling. Bone 2002; 30 (1): 2–4.
  • Dell RM, Adams AL, Greene DF, Funahashi TT, Silverman SL, Eisemon EO, et al. Incidence of atypical nontraumatic diaphyseal fractures of the femur. J Bone and Miner Res 2012; 27 (12): 2544–50.
  • Diab T, Condon KW, Burr DB, Vashishth D. Age-related change in the damage morphology of human cortical bone and its role in bone fragility. Bone 2006; 38 (3): 427–31.
  • Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 2009; 32 (9): 775–85.
  • Kajino Y, Kabata T, Watanabe K, Tsuchiya H. Histological finding of atypical subtrochanteric fracture after long-term alendronate therapy. J Orthop Sci 2011; 17 (3): 313–8.
  • Kidd LJ, Cowling NR, Wu A CK, Kelly WL, Forwood MR. Bisphosphonate treatment delays stress fracture remodeling in the rat ulna. J Orthop Res 2011; 29 (12): 1827–33.
  • Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB. Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 2001; 28 (5): 524–31.
  • Mohan PC, Howe TS, Koh J SB, Png MA. Radiographic features of multifocal endosteal thickening of the femur in patients on long-term bisphosphonate therapy. Eur Radiol 2012; 23 (1): 222–7.
  • Norman TL, Wang Z. Microdamage of human cortical bone: incidence and morphology in long bones. Bone 1997; 20 (4): 375–9.
  • Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak C YC. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 2005; 90 (3): 1294–301.
  • Perren SM. Physical and biological aspects of fracture healing with special reference to internal fixation. Clin Orthop 1979; (138): 175–96.
  • Russell R GG, Xia Z, Dunford JE, Oppermann U, Kwaasi A, Hulley PA, et al. Bisphosphonates: an update on mechanisms of action and how these relate to clinical efficacy. Ann N Y Acad Sci 2007; 1117: 209–57.
  • Saito M, Mori S, Mashiba T, Komatsubara S, Marumo K. Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs. Osteoporos Int 2008; 19 (9): 1343–54.
  • Schilcher J, Aspenberg P. Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop 2009; 80 (4): 413–5.
  • Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate Use and atypical fractures of the femoral shaft. N Engl J Med 2011; 364 (18): 1728–37.
  • Schilcher J, Koeppen V, Ranstam J, Skripitz R, Michaëlsson K, Aspenberg P. Atypical femoral fractures are a separate entity, characterized by highly specific radiographic features. A comparison of 59 cases and 218 controls. Bone 2013; 52 (1): 389–92.
  • Shane E, Burr D, Abrahamsen B, Adler RA, Brown TD, Cheung AM, et al. Atypical subtrochanteric and diaphyseal femoral fractures: Second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 2014; 29(1): 1-23.
  • Sloan AV, Martin JR, Li S, Li J. Parathyroid hormone and bisphosphonate have opposite effects on stress fracture repair. Bone 2010; 47 (2): 235–40.
  • Somford MP, Draijer FW, Thomassen BJ, Chavassieux PM, Boivin G, Papapoulos SE. Bilateral fractures of the femur diaphysis in a patient with rheumatoid arthritis on long-term treatment with alendronate: Clues to the mechanism of increased bone fragility. J Bone Miner Res 2009; 24 (10): 1736–40.
  • Weinstein RS, Roberson PK, Manolagas SC. Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 2009; 360 (1): 53–62.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.